HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Dec.31)-1st State-Level Device Policy,TCM Guideline,TCM Rally Unsustainable

The Concerns and Outlook About the Recent Rally in Traditional Chinese Medicine (TCM) Sector

China Healthcare Weekly (Jan.7)-China's Drug Spending,Logic Behind China/US Biotech, Anesthetics VBP

The CXO/Biotech Plunge and the Afterwards Investment Logic (2022)

2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties

China Healthcare Weekly (Dec.17)-The Most Important Policy in Next Three Years,Pacemaker VBP Results

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>The “capital arbitrage” in domestic innovative drug industry would not be sustainable.</li>
<li>Based on data, the sales and profits of innovative drugs at present can hardly support the current valuation of pharmaceutical companies (or recover the high cost of license-in deals).</li>
<li>However, we are still highly bullish on China healthcare industry if seen from the <strong>big picture</strong>.</li>
</ul>


The “capital arbitrage” in domestic innovative drug industry would not be sustainable.
Based on data, the sales and profits of innovative drugs at present can hardly support the current valuation of pharmaceutical companies (or recover the high cost of license-in deals).
However, we are still highly bullish on China healthcare industry if seen from the big picture.


China Healthcare Weekly (Dec.24)- Capital Arbitrage, Drug Commercial Results, Healthcare Big Picture